Short-term effects of fondaparinux and enoxaparin in patients with non-revascularization in the early stage of myocardial infarction
JIA Zhi
GUO Mu
ZHANG Yun-qiang
LIANG Hai-qing
ZHANG Li-yuan
SONG Yu
Abstract：Objective To explore the short-term clinical efficacy and safety of fondaparinux in non-revascularization in the early stage of myocardial infarction patients.Methods A total of 480 acute myocardial infarction patients (without undergoing early revascularization) were randomly divided into two groups:enoxaparin group (received enoxaparin 1 mg/kg q12 h or 0.75 mg/kg q12 h,if ＞ 75 years) and fondaparinux group (received fondaparinux 2.5 mg daily).The clinical effectiveness included major adverse cardiac events (MACE) and bleedings during 9 days,with the follow-up at 30 days and six months.Results Both the minor bleeding and total bleeding events were markedly fewer in fondaparinux group than those in enoxaparin group after 9 days treatment (7.9％ vs 18.3％,10.4％ vs 23.7％,HR:0.412,0.413,95％CI:0.241-0.706,0.258-0.662,P=0.001,P=0.000).Fondaparinux was associated with a significantly reduction of MACE at one month (15.4％ vs 24.6％,HR:0.600,95％CI:0.398-0.905,P =0.015) and a downward trend for MACE at six months (25.8％ vs 32.1％,HR:0.751,95 ％ CI:0.537-1.049,P =0.098).Conclusion Fondaparinux can effectively improve the short-term clinical efficacy in patients with non-revascularization in the early stage of myocardial infarction than enoxaparin,with lower bleeding incidence.
Keywords：Myocardial infarctionNon-revascularizationFondaparinuxPrognosis
Publication Date：2013-12-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1684-1687 )